# Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase

> **NCT04237337** · — · UNKNOWN · sponsor: **University Hospital, Caen** · enrollment: 200000 (estimated)

## Conditions studied

- Multiple Sclerosis
- Malignant Tumor

## Interventions

- **OTHER:** Exposure to MS drugs

## Key facts

- **NCT ID:** NCT04237337
- **Lead sponsor:** University Hospital, Caen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01
- **Primary completion:** 2020-02
- **Final completion:** 2020-03
- **Target enrollment:** 200000 (ESTIMATED)
- **Last updated:** 2020-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04237337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04237337, "Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04237337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*